ストックスクリーナーアプリを入手
9.18
0.51%
-0.05
前日終値:
$9.23
開ける：
$9.24
24時間の取引高:
179.58K
Relative Volume:
0.09
時価総額：
$1.20B
収益：
$745.97M
当期純損益:
$-99.21M
株価収益率:
-11.88
EPS:
-0.7729
ネットキャッシュフロー:
$-5.09M
1週間 パフォーマンス:
+9.45%
1か月 パフォーマンス:
+10.77%
6か月 パフォーマンス:
-24.29%
1年 パフォーマンス:
+23.93%
1日の値動き範囲:
$9.035
$9.2699
1週間の範囲:
$8.34
$9.36
52週間の値動き範囲:
$4.72
$13.74
Neogenomics Inc Stock (NEO) Company Profile
Compare NEO vs TMO, DHR, IDXX, WAT, A
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
NEO
Neogenomics Inc
|
9.18 | 1.20B | 745.97M | -99.21M | -5.09M | -0.7729 |
TMO
Thermo Fisher Scientific Inc
|
448.65 | 166.59B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
172.24 | 121.74B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
556.97 | 44.12B | 4.45B | 1.10B | 1.06B | 13.59 |
WAT
Waters Corp
|
342.06 | 33.62B | 3.77B | 449.25M | 240.68M | 7.8556 |
A
Agilent Technologies Inc
|
115.24 | 32.49B | 7.07B | 1.29B | 993.00M | 4.5355 |
Neogenomics Inc Stock (NEO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-07-30 | ダウングレード | BTIG Research | Buy → Neutral |
| 2025-07-29 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2025-05-15 | 開始されました | Guggenheim | Neutral |
| 2025-04-30 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2025-01-13 | ダウングレード | The Benchmark Company | Buy → Hold |
| 2024-12-10 | 開始されました | Jefferies | Buy |
| 2024-05-01 | 再開されました | Craig Hallum | Buy |
| 2023-12-29 | 繰り返されました | BTIG Research | Buy |
| 2023-08-21 | アップグレード | Stephens | Equal-Weight → Overweight |
| 2023-05-16 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2023-05-09 | アップグレード | BTIG Research | Neutral → Buy |
| 2023-02-24 | アップグレード | The Benchmark Company | Hold → Buy |
| 2023-02-01 | アップグレード | Needham | Hold → Buy |
| 2022-08-26 | ダウングレード | The Benchmark Company | Buy → Hold |
| 2022-08-22 | ダウングレード | Needham | Buy → Hold |
| 2022-06-03 | 開始されました | Piper Sandler | Overweight |
| 2022-03-29 | ダウングレード | BofA Securities | Buy → Neutral |
| 2022-03-29 | ダウングレード | Stephens | Overweight → Equal-Weight |
| 2022-01-18 | 再開されました | Stephens | Overweight |
| 2021-12-16 | 開始されました | Cowen | Outperform |
| 2021-11-05 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2021-10-14 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2021-06-03 | 開始されました | Goldman | Buy |
| 2021-02-25 | 再開されました | Needham | Buy |
| 2021-02-25 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2021-01-28 | 開始されました | Truist | Buy |
| 2020-12-11 | 再開されました | BTIG Research | Buy |
| 2020-10-28 | 繰り返されました | Needham | Buy |
| 2020-09-09 | 開始されました | Morgan Stanley | Overweight |
| 2020-08-28 | 開始されました | Guggenheim | Buy |
| 2020-07-29 | 繰り返されました | Needham | Buy |
| 2020-06-25 | 開始されました | BofA/Merrill | Buy |
| 2020-04-21 | 再開されました | Stephens | Overweight |
| 2020-03-02 | 再開されました | Craig Hallum | Buy |
| 2020-02-28 | アップグレード | First Analysis Sec | Outperform → Strong Buy |
| 2020-01-23 | ダウングレード | First Analysis Sec | Strong Buy → Outperform |
| 2019-10-30 | 繰り返されました | Needham | Buy |
| 2019-05-01 | 繰り返されました | Needham | Buy |
| 2019-03-29 | 繰り返されました | Needham | Buy |
| 2019-01-03 | 開始されました | Needham | Buy |
| 2018-10-24 | アップグレード | First Analysis Sec | Outperform → Strong Buy |
| 2018-08-21 | 開始されました | Leerink Partners | Outperform |
| 2018-05-02 | ダウングレード | First Analysis Sec | Overweight → Equal-Weight |
| 2017-09-11 | ダウングレード | BTIG Research | Buy → Neutral |
| 2017-08-24 | 開始されました | Gabelli & Co | Buy |
| 2016-12-15 | 開始されました | Cantor Fitzgerald | Overweight |
すべてを表示
Neogenomics Inc (NEO) 最新ニュース
NeoGenomics to Present New Research at ASCO Annual Meeting 2026 - Business Wire
(NEO) Risk Channels and Responsive Allocation - Stock Traders Daily
A Quick Look at Today's Ratings for NeoGenomics(NEO.US), With a Forecast Between $11 to $25 - Moomoo
Shareholders approve NeoGenomics (NASDAQ: NEO) equity plan amendment and board slate - Stock Titan
NeoGenomics Earnings Call Highlights NGS-Driven Momentum - TipRanks
NeoGenomics stock (US64049M2098): Q1 update keeps focus on cancer testing demand - AD HOC NEWS
NeoGenomics and Charles River Laboratories Shares Plummet, What You Need To Know - Yahoo Finance
NEOGENOMICS (NEO) 13G/A: Greenhouse reports 9,215,903 shares (7.1%) - Stock Titan
NeoGenomics signals $797M-$803M 2026 revenue outlook following PanTracer Liquid MolDX approval - MSN
Oncology diagnostics group NeoGenomics meets investors at May, June conferences - Stock Titan
NeoGenomics to Participate in Upcoming Investor Conferences - The Joplin Globe
(NEO) Movement as an Input in Quant Signal Sets - Stock Traders Daily
This NeoGenomics Insider Reduced Their Stake By 15% - Moomoo
Millennium group reports 2.22M NEO shares (1.7%) — Joint filing (NEO) - Stock Titan
NeoGenomics (NEO) EVP adds shares via RSU vesting while covering taxes - Stock Titan
NeoGenomics (NEO) COO exercises RSUs, withholds shares for taxes and holds 164,032 shares - Stock Titan
TradingKey - TradingKey
Is NeoGenomics’ Higher 2026 Revenue Outlook And Narrower Loss Profile Altering The Investment Case For NEO? - Sahm
NeoGenomics, Inc. (NASDAQ:NEO) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
NeoGenomics Inc. (NEO) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
NeoGenomics to Host Second Quarter 2015 Earnings Conference Call and Webcast Live on Thursday, July 23, 2015 - ACCESS Newswire
NEO PE Ratio & Valuation, Is NEO Overvalued - Intellectia AI
First Light, Mathew Arens report 10.8% stakes in Neogenomics (NEO) - Stock Titan
NeoGenomics (NEO) Q1 2026 Earnings Transcript - AOL.com
NEO SEC FilingsNeogenomics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
NeoGenomics Investor Alert - TMX Newsfile
NeoGenomics shares jump on earnings and analyst upgrades - MSN
NeoGenomics (NEO) CAO exercises RSUs, surrenders shares for taxes - Stock Titan
NeoGenomics (NEO) EVP updates equity awards, reports tax-withholding share move - Stock Titan
NeoGenomics (NEO) COO exercises RSUs, shares withheld for tax - Stock Titan
MSN Money - MSN
5 Insightful Analyst Questions From NeoGenomics’s Q1 Earnings Call - The Globe and Mail
NeoGenomics slides more than 5% despite fourth-quarter earnings beat - MSN
Liquidity Mapping Around (NEO) Price Events - Stock Traders Daily
NeoGenomics (NEO) Is Up 13.9% After Strong Q1 Revenue And New Epic Aura Integration - simplywall.st
NeoGenomics (NEO) Q1 2025 Earnings Transcript - AOL.com
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Opus Genetics (IRD), NeoGenomics (NEO) and Teladoc (TDOC) - The Globe and Mail
A Look At NeoGenomics (NEO) Valuation After Q1 2026 Results And Epic Aura Oncology Integration - Yahoo Finance
BTIG Maintains NeoGenomics(NEO.US) With Hold Rating - Moomoo
Vanguard holds 6.61M NeoGenomics shares (NEO) — 5.09% stake - Stock Titan
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
NeoGenomics reports Q1 revenue increase - Gulfshore Business
NeoGenomics Reports First Quarter 2026 Financial Results - HarianBasis.co
Leerink Partners upgrades NeoGenomics (NEO) - MSN
Analysts Offer Insights on Healthcare Companies: NeoGenomics (NEO), CG Oncology, Inc. (CGON) and Icon (ICLR) - The Globe and Mail
NeoGenomics Earnings Call Highlights NGS-Led Growth - TipRanks
TD Cowen Issues Positive Forecast for NeoGenomics (NASDAQ:NEO) Stock Price - MarketBeat
Vanguard Portfolio Management holds 5.91% of NeoGenomics (NEO) common stock - Stock Titan
Leerink upgrades Neogenomics stock rating on oncology growth outlook By Investing.com - Investing.com Nigeria
NeoGenomics (NASDAQ:NEO) Shares Gap Up Following Analyst Upgrade - MarketBeat
NeoGenomics (NASDAQ:NEO) Upgraded by Leerink Partners to Outperform Rating - MarketBeat
Neogenomics Inc (NEO) 財務データ
収益
当期純利益
現金流量
EPS
0.23%
0.65%
大文字化:
|
ボリューム (24 時間):